A Comparison of Pharmacokinetics between Humans and Monkeys

To verify the availability of pharmacokinetic parameters in cynomolgus monkeys, hepatic availability (Fh) and the fraction absorbed multiplied by intestinal availability (FaFg) were evaluated to determine their contributions to absolute bioavailability (F) after intravenous and oral administrations. These results were compared with those for humans using 13 commercial drugs for which human pharmacokinetic parameters have been reported. In addition, in vitro studies of these drugs, including membrane permeability, intrinsic clearance, and p-glycoprotein affinity, were performed to classify the drugs on the basis of their pharmacokinetic properties. In the present study, monkeys had a markedly lower F than humans for 8 of 13 drugs. Although there were no obvious differences in Fh between humans and monkeys, a remarkable species difference in FaFg was observed. Subsequently, we compared the FaFg values for monkeys with the in vitro pharmacokinetic properties of each drug. No obvious FaFg differences were observed between humans and monkeys for drugs that undergo almost no in vivo metabolism. In contrast, low FaFg were observed in monkeys for drugs that undergo relatively high metabolism in monkeys. These results suggest that first-pass intestinal metabolism is greater in cynomolgus monkeys than in humans, and that bioavailability in cynomolgus monkeys after oral administration is unsuitable for predicting pharmacokinetics in humans. In addition, a rough correlation was also observed between in vitro metabolic stability and Fg in humans, possibly indicating the potential for Fg prediction in humans using only in vitro parameters after slight modification of the evaluation system for in vitro intestinal metabolism.

[1]  R. Davies,et al.  Timolol and propranolol: Bioavailability, plasma concentrations, and beta blockade , 1982, Clinical pharmacology and therapeutics.

[2]  M. Niemi,et al.  Functional interaction of intestinal CYP3A4 and P‐glycoprotein , 2004, Fundamental & clinical pharmacology.

[3]  D. Shand,et al.  The Disposition of Propranolol , 1972 .

[4]  M. Kobayashi,et al.  A highly sensitive method to assay FK-506 levels in plasma. , 1987, Transplantation proceedings.

[5]  R. G. Mcallister,et al.  The Pharmacology of Verapamil , 1983 .

[6]  J. Lin,et al.  Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. , 1997, Biochemical pharmacology.

[7]  Paul W. Buehler,et al.  Comparison of Oral Absorption and Bioavailability of Drugs Between Monkey and Human , 2002, Pharmaceutical Research.

[8]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[9]  Exploratory population pharmacokinetics (e-PPK) analysis for predicting human PK using exploratory ADME data during early drug discovery research , 2009, European Journal of Drug Metabolism and Pharmacokinetics.

[10]  L. A. Fenu,et al.  Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs , 2007, Drug Metabolism and Disposition.

[11]  D. Greenblatt,et al.  Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration. , 1977, The Journal of pharmacology and experimental therapeutics.

[12]  M. Fisher,et al.  The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective. , 2007, Current drug metabolism.

[13]  P. Artursson,et al.  Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  Shufeng Zhou,et al.  Drug-herb interactions: eliminating toxicity with hard drug design. , 2006, Current pharmaceutical design.

[15]  Y. Sugiyama,et al.  Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[16]  M. Fromm,et al.  The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[17]  T. Kamataki,et al.  Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism? , 2007, Archives of biochemistry and biophysics.

[18]  P. Welling,et al.  Bioavailability of hydrochlorothiazide from tablets and suspensions. , 1984, Journal of pharmaceutical sciences.

[19]  C. Ditzler,et al.  Bioavailability of oral dexamethasone , 1975, Clinical pharmacology and therapeutics.

[20]  Y. Kato,et al.  Asymmetric Intestinal First-Pass Metabolism Causes Minimal Oral Bioavailability of Midazolam in Cynomolgus Monkey , 2007, Drug Metabolism and Disposition.

[21]  S. Yamashita,et al.  Characterization of gastrointestinal drug absorption in cynomolgus monkeys. , 2008, Molecular pharmaceutics.

[22]  P. Wallemacq,et al.  Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours. , 1993, Clinical chemistry.

[23]  Hans Larsson,et al.  Pharmacokinetics of propranolol , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[24]  N. Undre,et al.  The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[25]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[26]  J. Pybus,et al.  Measurement of serum lithium by atomic absorption spectroscopy. , 1970, Clinical chemistry.

[27]  Per Artursson,et al.  Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA method , 2005 .

[28]  E. Kirsten,et al.  The Pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses , 1982 .

[29]  P. Hinderling,et al.  Pharmacokinetics of Digoxin and Main Metabolites/Derivatives in Healthy Humans , 1991, Therapeutic drug monitoring.

[30]  Masato Chiba,et al.  Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[31]  David S. Wishart,et al.  Improving Early Drug Discovery through ADME Modelling , 2007 .

[32]  D K Yu,et al.  The Contribution of P‐glycoprotein to Pharmacokinetic Drug‐Drug Interactions , 1999, Journal of clinical pharmacology.

[33]  D. Shand,et al.  The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. , 1973, The Journal of pharmacology and experimental therapeutics.

[34]  U. Fagerholm.  Prediction of human pharmacokinetics—gut‐wall metabolism , 2007, The Journal of pharmacy and pharmacology.

[35]  Mangan Kf.  Immunologic control of hemopoiesis: implications for quality of the graft after allogeneic bone marrow transplantation. , 1987 .

[36]  T. Walle,et al.  Presystemic and systemic glucuronidation of propranolol , 1979, Clinical pharmacology and therapeutics.

[37]  W. Martin,et al.  Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. , 1990, Biopharmaceutics & drug disposition.

[38]  D. Shen,et al.  Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. , 1997, Advanced drug delivery reviews.

[39]  T. Akabane,et al.  Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[40]  Masoud Jamei,et al.  Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.

[41]  E. Kirsten,et al.  The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. , 1983, Clinical pharmacology and therapeutics.

[42]  T Iwatsubo,et al.  PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS , 1996, Biopharmaceutics & drug disposition.

[43]  A. Arancibia,et al.  Absorption and disposition kinetics of lithium carbonate following administration of conventional and controlled release formulations. , 1986, International journal of clinical pharmacology, therapy, and toxicology.

[44]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.